Current therapies and advances in the treatment of pancreatic cancer
- 1 June 2006
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 58 (3) , 231-241
- https://doi.org/10.1016/j.critrevonc.2006.02.004
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the PancreasJournal of Clinical Oncology, 2006
- Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal GroupJournal of Clinical Oncology, 2005
- Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2005
- The Virginia Mason approach to localized pancreatic cancerSurgical Oncology Clinics of North America, 2004
- Chemotherapy for Pancreatic CancerNew England Journal of Medicine, 2004
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological studyBritish Journal of Surgery, 1995
- Chemotherapy prolongs survival in inoperable pancreatic carcinomaBritish Journal of Surgery, 1994
- Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater—results of a controlled, prospective, randomised multicentre studyEuropean Journal Of Cancer, 1993
- Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.BMJ, 1980